{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Galmed Pharmaceuticals Ltd."},"Symbol":{"label":"Symbol","value":"GLMD"},"Address":{"label":"Address","value":"16 TIOMKIN STREET, TEL AVIV, 6578317, Israel"},"Phone":{"label":"Phone","value":"+972 36938448"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis."},"CompanyUrl":{"label":"Company Url","value":"https://www.galmedpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Allen Baharaff","title":"Chairman, President & Chief Executive Officer"},{"name":"Guy Nehemya","title":"Chief Operating & Data Protection Officer"},{"name":"Liat Hayardeny","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}